A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

FRIDAY, June 6, 2025 (HealthDay News) — A repurposed diabetes drug can be an effective tool against fatty liver disease, a ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 ...

Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...

Dapagliflozin is indicated for both type 2 diabetes and heart failure. It can do the following: improve management of blood sugar and reduce the risk of hospitalization for heart failure in adults ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Diabetes remission was achieved in 44 and 28% of patients in the dapagliflozin and placebo groups, respectively. HealthDay News — For patients with overweight or obesity and type 2 diabetes ...

ANSWER: Both prediabetes and diabetes are metabolic abnormalities in which the body cannot use sugar properly. There are ...

FRIDAY, Jan. 24, 2025 (HealthDay News) -- People can reverse their type 2 diabetes through a combination of calorie cutting and medication, a small clinical trial says. Overweight and obese adults ...